Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Pharmacognosy wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Electronic prescribing wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
International and Canadian Standards: Ethics and Regulatory Melanie Walker, PhD Candidate Learning Objectives Understand: 1. Clinical trial regulations and guidelines in Canada 2. International regulations and how they differ from Canada (USA, European Union) 3. Investigator responsibilities for compliance with regulations and guidelines Not a learning objective… Canada Ethics / Regulatory Approvals of Clinical Trials in Canada Ethics Approval – Conducted by Research Ethics Boards: • institutional (local) or central board or both – Mandated by any/all: • institution • funding source/agency • Health Canada regulations Regulatory Approval – Conducted by Gov’t regulatory agencies: • Health Products and Food Branch of Health Canada – Mandated by: • Clinical Trial Regulations for Drugs • Medical Devices Regulations • Natural Health Products Regulations Current Ethics Guidelines/ Regulations Applicable to Clinical Trials in Canada • Vary by trial • Invoked/required by: – use of human subjects – source of funding – intervention being studied – local/institutional requirements Applicable Guidelines/Regulations • Any Medical Research involving humans Nuremberg Code Declaration of Helsinki Local/Specific requirements (i.e. REB, hospital, university, industry or other sponsor) Applicable Guidelines/Regulations (cont’d) • Human Research funded by Canadian federal granting agencies (CIHR, Tri-council Policy Statement NSERC, SSHRC) • Human Research funded by US federal funds (i.e. National Institutes of Health (NIH)) US Federal Regulations re: Human Subjects Protections NIH Guidelines Applicable Guidelines/Regulations (cont’d) • Clinical Trials Involving Drugs Canada: Health Canada Food and Drug Act Regulations re: Clinical Trials US: FDA Regulations ICH - Good Clinical Practice Guidelines (ICH-GCP) Applicable Guidelines/Regulations (cont’d) • Clinical Trials Involving Natural Health Products • Clinical Trials Involving Medical Devices Natural Health Products Regulations (Health Canada) Medical Devices Regulations (Health Canada) Nuremberg Code • 10 standards physicians must conform to when carrying out experiments on humans i.e. – Informed Consent -- participation voluntary – Research must be necessary & based on prior animal experimentation – Risk proportionate to importance – No unnecessary physical/mental suffering – Freedom to withdraw participation at any time Declaration of Helsinki • Medical progress based on research; research improves treatments and understanding of disease but involves risks and burdens; must be subject to ethical standards • Content of protocol • Compliance with Declaration • Independent REB must give continuing approval • Well-being of subject overrides interests of science/ society • Voluntary and informed participation • Protect privacy and confidentiality of subjects • Informed consent requirements • Publication requirements REB Guidelines/Requirements • Address – Requirement for SOPs – Membership – Types of approval – What information must be provided to the REB – What must be approved by the REB (protocol, informed consent, patient information, advertisements etc) Tri-Council Policy Statement (TCPS) Ethical Conduct for Research Involving Humans • Policy statement for Canadian Granting Agencies: – CIHR-Canadian Institute for Health Research (formerly MRC) – NSERC-Natural Sciences & Engineering Research Council – SSHRC (Social Sciences and Humanities Research Council) • Granting agencies will only fund individuals and institutions which certify compliance • No force of law in Canada, but a widely adopted ethical standard for human research • Compliance/monitoring programs being considered TCPS: Content • REB membership – Number – Composition • REB procedures for reviewing research – Documents/Events – Level of review – Meeting procedures – Record Keeping • Free and Informed Consent – Evidenced in writing – Necessary consent elements listed • Privacy and confidentiality • Conflicts of Interest • Clinical Trials • Human Genetic Research • Human Tissue US Federal Regulations • US Code of Federal Regulations Title 45, Part 46, Protection of Human Subjects • Includes research funded by the US National Institutes of Health (NIH) or it’s agencies (i.e. National Cancer Institute or NCI US) – Ethics education requirement for researchers working on NIH funded projects – NIH collect CVs, FD and 1572’s annually – investigator # • OHRP (US Office for Human Subjects Protection) ensures compliance with this policy – Assurance required for each participating site US CFR Title 45, Part 46 • REB membership and function • Level of review (expedited/full board) • Informed consent requirements • REB and Institutional Assurances must be obtained • Documentation of HIPAA compliance (patient authorization) Canada Food & Drug Act Regulations • Part C, Division 5: “Drugs for Clinical Trials Involving Human Subjects” • Apply to clinical trials involving: – Investigational drugs (i.e. drugs that are not marketed, approved for use, in Canada) or – Marketed drugs being used outside of their approved use in Canada • i.e. clinical use, dose/formulation, route of administration or target patient population Clinical Trials Regulations • Require the submission of a ‘Clinical Trials Application’ (CTA), formerly called an Investigational New Drug Application (IND) – Protocol, consent, drug information, investigator brochure • CTA Submitted to Health Canada – 30 day review period – No objection letter issued Clinical Trials Regulations Require… • Approved Clinical Trials Application (CTA) • Compliance with ICH-Good Clinical Practice Guidelines • Submission and approval of changes to the protocol (i.e. amendments, revisions) • Drug labeled specifically for the trial • Investigator signature on ‘Qualified Investigator Undertaking Form’ which indicates agreement to perform trial in accordance with GCP • Notification of pre-mature discontinuation of the trial • Reporting serious adverse reactions • Health Canada may inspect (audit) sponsors and/or sites participating on trials Clinical Trials Regulations Ethics Requirements • Protocols and any changes to protocols (including informed consent) must be approved by an REB • REB composition defined in regulations (similar to Tri-Council composition + Cdn component) • REB chair must sign an attestation (agrees to follow Health Canada regulations, ICH-GCP) • REB refusals to approve a protocol or changes to a protocol must be reported to Health Canada US Food and Drug Administration (FDA) Regulations • Applicable to studies conducted in Canada where Study is being done directly under a US IND • US INDs required when: – Drug (s) is not marketed Or – Drug is marketed but one of the following conditions exist: – intention to submit trial to FDA as a well-controlled study – intention to change labeling as a result of study results – indication/dose etc. involves a significant increase in risk US Food and Drug Administration (FDA) Regulations • Regulations: – Code of Federal Regulations, Title 21, Section 312 – Require the submission of an Investigational New Drug Submission (IND) – Requirements for labeling, safety reporting, investigators, REB review etc. specified in regs • In practical terms – FDA 1572 required – FDA Financial disclosure required ICH Good Clinical Practice Guideline (GCP) • International ethical and scientific quality standard for trials involving humans. It addresses: – Design; conduct; recording; reporting Follow when conducting a trial: • Intended for submission to a regulatory agency in an ICH region • Any trial being conducted under a Clinical Trials Application in Canada ICH-GCP • GCP: Basic Structure – 1. Glossary – 2. Principles – 3. REB responsibilities – 4. Investigator responsibilities – 5. Sponsor responsibilities – 6. Protocol and amendments – 7. Investigator Brochure – 8. Essential Documents GCP: Principles 1. ethical principles 2. benefits/risk 3. rights/safety of subjects most important 7. medical care by a qualified physician 8. qualified individuals conduct trials 9. free informed consent 4. drug info supports trial 10 data accurate etc. 5. trial scientifically sound, protocol 11. confidentiality 6. protocol REB approved 12. drugs: GMP/protocol 13. quality assurance GCP: Research Ethics Board (REB) Responsibilities • Composition, function and procedures • Documents to obtain & review • Records GCP: Investigator Responsibilities • Qualifications & resources • Care of subjects • Communication with REB • Drug • Patient consent process • Records/reports • Safety reporting GCP: Sponsor Responsibilities • Quality assurance and quality control • Trial management, data handling and record keeping • Investigator selection • Regulatory submissions • Confirmation of REB review • Drug • Informed consent requirements • Serious Adverse Event Reporting • Monitoring & Auditing – patients rights/well-being protected – data is accurate, complete, verifiable • Conduct of trial by everyone is GCP compliant Summary of Applicable Regulations and Guidelines by Trial Type REB GCP TCPS HC OHRP All human trials √ DOH √ CTA NIH √ + New indication √ √ √ √ US Govt funding / drug √ √ √ ± Under US IND √ √ √ ± √ FDA ± √ Summary of Investigator Requirements • Appropriately qualified by education and training • Qualifications (curriculum vitae) on file • Complete/file required forms (i.e. Health Canada Qualified Investigator form) • Declare financial conflicts of interest (i.e. own a company) to REB, sponsor, subjects – in some cases, should not conduct trial • Training on trial protocol • NIH ethics education certificate (if applicable) International Standards Background • Regulations that apply to trials conducted in Canada are described in previous section • Even if Canadian centres are not subject to international regulations, may be of interest/relevance when participating in international trials may impact on overall protocol conduct / logistics USA: Food and Drug Agency (FDA) • Largest market. Pharmaceutical companies are US-driven in their registration / development plans – Trials may be conducted under a US IND • May receive comments from the FDA requiring protocol amendments even after approved by Health Canada – Even if not conducted under a US IND, protocol may be submitted for Special Protocol Assessment if NDA planned • May have to amend protocol based on FDA comments USA FDA • IND is drug specific. Once an IND is in place, any new trials are ‘filed’ to the IND. The FDA have 30 days to comment, but no formal approval is given (no news is good news): BUT they may issue a ‘Clinical Hold’ • In Canada, each trial has a unique CTA & NOL. The Drug is filed under a Drug Master File, and each CTA submitted must cross reference that DMF. FDA • Unless the trial is conducted under a US IND, FDA1572 and financial disclosures are not needed – even if later FDA NDA is planned. • If the trial is conducted under an IND – Must conform to US regulations including REB and informed consent regulations – Essentially = HC/GCP requirements + 1572 / FD forms European Union • EuD-CT issued in 2001 (2001/20/EC) • Member states implemented thereafter • Essentially addresses GCP implementation in clinical trials EuD-CT • Trials require regulatory approval (Ph I exempt) and have EUDRACT number • Investigational Medicinal Product – Manufactured to GMP authorization needed • Trial pharmacy/MD may pack / label for the trial – Trial medications supplied to patient free of charge • All trials conducted to GCP • Regulatory authority enforcement • Safety surveillance – SUSARs • Report to RAs and investigators for sponsors trials • Report to EU central pharmacovigilance database – SSARs • Annual listing to RA and REBs for sponsors trial Checklists Keeping Track of Your Responsibilities….. Prior to Opening Trial What regulations apply? Can your REB comply (i.e. OHRP)? Investigator qualifications, CV, conflicts, trial training Prepare ethics and regulatory binders Submit a CTA if required; letter for cross-filing to DMF; drug labels NB Ensure TCPS, GCP, HC compliance Informed consent – include all required elements and risks Initial full board REB approval – submit all required information/documents During the Trial Informed consent prior to trial specific procedures Comply with the protocol, document/report if not Source documents Maintain essential documents (GCP) Maintain confidentiality Ensure drug reconciliation / compliance with regs Ongoing annual approval (full board if OHRP) REB & HC approval for amendments/changes (may be post-hoc if immediate safety hazard) End of the Trial Inform REB and HC when trial closes Submit Final report to REB Monitor long term safety : inform patients and REB as needed Retain records (included source documents and radiology) according to regulations (25 years for CTA trial) Audits/inspections may occur during trial or after final analysis